Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Envoy Medical (COCH) Shares Outstanding (Weighted Average) (2021 - 2026)

Envoy Medical's Shares Outstanding (Weighted Average) history spans 6 years, with the latest figure at $68.9 million for Q1 2026.

  • On a quarterly basis, Shares Outstanding (Weighted Average) rose 223.23% to $68.9 million in Q1 2026 year-over-year; TTM through Mar 2026 was $68.9 million, a 223.23% increase, with the full-year FY2025 number at $23.3 million, up 23.78% from a year prior.
  • Shares Outstanding (Weighted Average) hit $68.9 million in Q1 2026 for Envoy Medical, up from $2.1 million in the prior quarter.
  • Over the last five years, Shares Outstanding (Weighted Average) for COCH hit a ceiling of $68.9 million in Q1 2026 and a floor of $664883.0 in Q4 2024.
  • Historically, Shares Outstanding (Weighted Average) has averaged $21.3 million across 5 years, with a median of $18.6 million in 2024.
  • Biggest five-year swings in Shares Outstanding (Weighted Average): plummeted 94.59% in 2024 and later soared 223.23% in 2026.
  • Tracing COCH's Shares Outstanding (Weighted Average) over 5 years: stood at $10.1 million in 2022, then rose by 21.46% to $12.3 million in 2023, then plummeted by 94.59% to $664883.0 in 2024, then surged by 211.94% to $2.1 million in 2025, then surged by 3223.75% to $68.9 million in 2026.
  • Business Quant data shows Shares Outstanding (Weighted Average) for COCH at $68.9 million in Q1 2026, $2.1 million in Q4 2025, and $21.9 million in Q3 2025.